Management of patients with cognitive impairment.
Nevrologiya, Neiropsikhiatriya, Psikhosomatika
; 15(1):97-102, 2023.
Article
in Russian
| EMBASE | ID: covidwho-2317998
ABSTRACT
The management of patients with cognitive impairment (CI) is one of the urgent problems of modern medicine. Issues of diagnostics and therapy of patients with CI and their high mortality during the period of coronavirus infection are discussed. A wide prevalence of patients with mild CI (MCI), an important role of neuropsychological research in establishing CI, and frequent diagnosis of CI only at the stage of dementia were noted. In our country, CI is poorly diagnosed, the most common cause of CI in the elderly - Alzheimer's disease (AD) - is rarely established, patients are observed for a long time with a diagnosis of cerebrovascular disease (CVD). Some non-drug and drug methods can reduce the manifestations of CI, improve the quality of life of both the patients themselves and those around them. In severe CI, socio-psychological methods, stimulating patients to feasible household and social, physical and mental activity, and avoiding prolonged hospitalization are of primary importance. In addition to lifestyle changes, much attention in CI is given to the prevention of stroke, the treatment of arterial hypertension and diabetes mellitus. At the stage of dementia, cholinomimetic drugs (acetylcholinesterase inhibitors, donepezil, rivastigmine, galantamine) and the glutamate receptor blocker memantine are used. The use of choline alfoscerate in CI and the results of the multicenter, placebo-controlled ASCOMALVA study are discussed, in which, in patients with AD and CVD, the addition of choline alfoscerate to donepezil reduced the severity of CI, manifestations of depression, anxiety, and apathy. A new oral form of choline alfoscerate (Cerpechol) is reported that may improve patient compliance and be used in patients with swallowing disorders.Copyright © 2023 Ima-Press Publishing House. All rights reserved.
Alzheimer's disease; Cerpexol; choline alfoscerate; dementia; mild cognitive impairment; vascular cognitive impairment; Alzheimer disease; anxiety; apathy; cerebrovascular accident; cerebrovascular disease; cognitive defect/dt [Drug Therapy]; dementia/dt [Drug Therapy]; depression; diabetes mellitus; disease severity; human; hypertension; lifestyle modification; medication compliance; mental performance; patient care; physical activity; quality of life; review; choline alfoscerate/dt [Drug Therapy]; choline alfoscerate/po [Oral Drug Administration]; cholinergic receptor stimulating agent/dt [Drug Therapy]; cholinesterase inhibitor/dt [Drug Therapy]; donepezil/dt [Drug Therapy]; galantamine/dt [Drug Therapy]; memantine/dt [Drug Therapy]; rivastigmine/dt [Drug Therapy]; cerpechol
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
Russian
Journal:
Nevrologiya, Neiropsikhiatriya, Psikhosomatika
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS